Gilead Sciences announced the closing of its $7.8 billion acquisition of Arcellx, a specialty biopharma focused on cell‑therapy technologies, on April 28 2026. The deal was paid in cash at $115 per share, plus a $5 per share contingent value right that will trigger if anito‑cel, Arcellx’s next‑generation CAR‑T product for multiple myeloma, achieves cumulative global net sales of at least $6 billion by the end of 2029.
The transaction gives Gilead full ownership of anito‑cel and its D‑Domain binder platform, which is designed to deliver high CAR expression without tonic signaling and to release quickly from the BCMA target. Anito‑cel has Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations, and its BLA for relapsed or refractory multiple myeloma was accepted by the FDA with a PDUFA action date of December 23 2026.
Strategically, the acquisition adds a late‑stage asset to Gilead’s Kite platform and revives a cell‑therapy business that has seen declining sales in recent years. By integrating Arcellx’s manufacturing capabilities, Gilead can accelerate the commercialization of anito‑cel and position itself to capture a share of the large multiple‑myeloma market, which is projected to grow to $30 billion by 2030. The deal also diversifies Gilead’s revenue mix, which in 2025 was dominated by HIV products that accounted for roughly 70% of total sales.
Financially, the acquisition is expected to be modestly dilutive to Gilead’s earnings per share in 2026 and 2027, with a projected dilution of $5.57 billion to $5.67 billion. From 2028 onward, the transaction is projected to become accretive as anito‑cel gains regulatory approval and generates sales. The deal also provides a foundation for future pipeline development, as the D‑Domain binder technology could be applied to other oncology programs.
Gilead’s HIV franchise, which generated about $20.7 billion in 2025, remains a core revenue driver, but the company has been actively investing in oncology and cell therapy to reduce its reliance on that segment. The acquisition of Arcellx is a key step in that diversification strategy, adding a high‑potential product to a platform that has struggled to achieve commercial success in recent years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.